Y-Intercept (HK)’s Adverum Biotechnologies ADVM Stock Holding History

Y-Intercept (HK)’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,122	Closed	-$45.4K	–	1520
2025 Q2	$45.4K	Buy	+21,122	New	+$59.1K	﹤0.01%	1563
2022 Q3	–	Sell	-1,130	Closed	-$14K	–	930
2022 Q2	$14K	Buy	+1,130	New	+$11.8K	﹤0.01%	800

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Y-Intercept (HK)'s ADVM Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Adverum Biotechnologies (ADVM) in Q3 2025, closing a stake of 21,122 shares — an estimated $45.4K sold.

Y-Intercept (HK) first reported a position in ADVM in Q2 2022 and held it in 2 quarters. The position peaked at $45.4K in Q2 2025. 50 funds tracked by Wall St. Rank hold ADVM as of Q3 2025.

Y-Intercept (HK) reported no remaining Adverum Biotechnologies position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 21,122 Adverum Biotechnologies shares in Q3 2025, an estimated $45.4K.
Y-Intercept (HK) first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 2 quarters.
Y-Intercept (HK)'s Adverum Biotechnologies position peaked at $45.4K in Q2 2025.
50 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.